Result for
Topic: Vaccines and Immunity
December 3, 2020
Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets
Using machine learning predictions and clinical data from convalescent COVID-19 patients, Liu et al. developed a vaccine design that would incorporate enough pathogen components to elicit an immune response across a diverse population of people. The study also indicates that current vaccine candidates, which are largely based only on the SARS-CoV-2 spike protein and receptor…
Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
Exposure to SARS-CoV-2 could induce virus-specific T-cell responses without inducing virus-specific antibody responses. In a study including 11 SARS-CoV-2 serodiscordant couples staying in the same household in which 1 of the 2 partners had lab-confirmed and mild symptomatic COVID-19, the index partners who were initially infected displayed SARS-CoV-2-specific antibody and T-cell responses up to 102…
The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Interim guidance from The Advisory Committee on Immunization Practices (ACIP) recommends that both 1) health care personnel and 2) residents of long-term care facilities (LTCF) be offered a COVID-19 vaccine in the initial phase of the vaccination program. As of December 1, approximately 245,000 COVID-19 cases and 858 COVID-19-associated deaths had been reported among U.S….
December 2, 2020
High Seroprevalence but Short‐lived Immune Response to SARS‐CoV‐2 Infection in Paris
Serological testing among 1847 active workers in France showed declining antibody responses to SARS‐CoV‐2 4-8 weeks after the first sampling. Overall, 11% of workers were positive for IgG against SARS-CoV-2-specific proteins and 9.5% had evidence of viral neutralization. Among these, 21% were asymptomatic. In sera obtained 4–8 weeks after the first sampling, anti‐N and anti‐S…
December 1, 2020
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Among 177 SARS-CoV-2 positive individuals from the UK, 15 (9%) did not seroconvert during the entire 60-day follow-up period, suggesting that a minority of infected persons may not develop detectable IgG against SARS-CoV-2. Persons who seroconverted were older compared to those who did not seroconvert (median age 66 vs 41 years) and were more likely…
Risk Exposures Risk Perceptions Negative Attitudes toward General Vaccination and COVID-19 Vaccine Acceptance among College Students in South Carolina
[Pre-print, not peer reviewed] Online survey data from 1,062 college students in South Carolina suggest that perceived severity and fear of COVID-19 were positively associated with COVID-19 vaccine acceptance, while a higher level of risk exposures and negative attitude toward vaccines in general were associated with low COVID-19 vaccine acceptance. Qiao et al. (Nov 30,…
Willingness to Vaccinate against COVID-19 in the US Longitudinal Evidence from a Nationally Representative Sample of Adults from April-October 2020
[Pre-print, not peer reviewed] Willingness to receive a SARS-CoV-2 vaccine declined from 71% in April to 54% in October among US adults, according to longitudinal data from a nationally representative sample (n=7,547). The decline was primarily driven by an increase in participants undecided about being vaccinated and unwilling to be vaccinated. Participants without a college…
November 30, 2020
Dynamic Changes in Anti-SARS-CoV-2 Antibodies during SARS-CoV-2 Infection and Recovery from COVID-19
An analysis of laboratory tests from 1850 patients hospitalized with COVID-19 showed changes in SARS-CoV-2 antibody levels over time, and that levels of spike protein (S)- or receptor-binding domain (RBD)-specific IgG were important in viral clearance and recovery. Generation of S-, RBD-, and nucleoprotein (N)-specific IgG occurred one week later in patients with severe COVID-19…
November 25, 2020
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
A repeated cross-sectional study carried out in all 50 US states, the District of Columbia, and Puerto Rico found that although SARS-CoV-2 seroprevalence varied between 1% and 23%, fewer than 10% of people nationally had detectable antibodies. A total of 177,919 samples were obtained during four periods between July 27 and September 24, 2020 from…
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020
Among 156 frontline health care personnel who had positive SARS-CoV-2 antibody test results in spring 2020, 146 (94%) experienced a decline in antibody concentrations at repeat testing approximately 60 days later. In addition, 28% had seroreverted (negative antibody test). Individuals with higher initial antibody responses were more likely to have antibodies detected at the follow-up…
Previous page Next page